Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Katja Weisel, Meletios Dimopoulos, Philippe Moreau, Munci Yagci, Alessandra Larocca, Abraham S. Kanate, Filiz Vural, Nicola Cascavilla, Supratik Basu, Peter Johnson, Peter Byeff, Marek Hus, Paula Rodriguez-Otero, Ercan Muelduer, Pekka Anttila, Patrick J. Hayden, Maria-Theresa Krauth, Paulo Lucio, Dina Ben-Yehuda, Larisa MendeleevaShien Guo, Xin Yu, Lara Grote, Tsvetan Biyukov, Sujith Dhanasiri, Paul Richardson

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Originalspråkengelska
TidskriftLeukemia & lymphoma
Volym61
Utgåva8
Sidor (från-till)1850-1859
Antal sidor10
ISSN1042-8194
DOI
StatusPublicerad - 2 jul 2020
MoE-publikationstypA1 Tidskriftsartikel-refererad

Vetenskapsgrenar

  • 3122 Cancersjukdomar

Citera det här